Screener / SEC EDGAR /CIK 0001568651 /10-K filed Feb 13, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Financials · Health Insurance

Oscar Health, Inc. OSCR

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What OSCR's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full

Open on SEC

Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook

Oscar Health, Inc. (“Oscar Health” or the “Company”) (NYSE: OSCR) announced today its financial results for the third quarter ended September 30, 2026, and updates to its full year 2026 outlook.

“Oscar Health is on track to deliver the strongest year of financial performance in our history, and we are raising our earnings from operations outlook for a third time,” said Mark Bertolini, CEO of Oscar Health. “The ACA is the foundation of a rapidly-developing individual market in America, and Oscar Health is built to lead it. Our disciplined pricing, consumer-led products, and technology-powered approach are driving stronger economics and position us to grow market share and expand margin in 2027.”

Three Months Nine Months Ended Ended September 30, September 30, (in thousands, 2026 2025 2026 2025 except percentages) Total revenue $5,139,298 $2,985,984 $14,666,712 $8,896,192 Medical loss 84.0% 88.5% 78.1% 84.8% ratio (“MLR”) Selling, general, and administrati… 14.0% 17.5% 14.4% 17.3% (“SG&A”) expense ratio Earnings (loss) from $178,018 $(129,250) $1,270,738 $(62,610) operations Net income (loss) attributable $167,281 $(137,450) $1,208,085 $(90,540) to Oscar Health, Inc. Adjusted $206,852 $(101,453) $1,349,273 $27,971 EBITDA(1) (1) Adjusted EBITDA is a non-GAAP measure. See “Key Operating and Non-GAAP Financial Metrics - Adjusted EBITDA” in this release for a reconciliati… to net income, the most directly comparable GAAP measure, and for information regarding Oscar Health’s use of Adjusted EBITDA.

As of September 30, Effectuated Membership by Offering 2026 2025 Individual and Small Group(1) 2,691,885 2,111,736 Cigna+Oscar(2) — 5,168 Total Members(3) 2,691,885 2,116,904 (1) Membership includes members enrolled through a Custom Health Option and Individual Care Expense Arrangement (“CHOICE”). 2025 membership includes small group members. The Company no longer offers small group plans effective December 15, 2024. (2) Represents total membership for our former co-branded partnership with Cigna. We did not renew the Cigna+Oscar Small Group arrangement after its initial term ended on December 31, 2024. (3) Represents effectuated members. Effectuated members are those who are actively enrolled in one of our plans and whose required premium payments have either been made or are within the payment grace period. A member covered under more than one of our health plans counts as a single member for the purposes of this metric.

2026 Financial Guidance Summary Prior Full Updated Full Year 2026 Year 2026 Outlook Outlook (in thousands, Low High Low High except percentage… Total $18.7 $19.0 $19.0 billion $19.3 revenue(1) billion billion billion Medical loss 81.0% 82.0% 80.5% 81.5% ratio(2) SG&A expense 15.6% 16.1% 15.1% 15.6% ratio(3) Earnings from $600 million $800 million $850 million $950 million operations… (1) Total revenue includes premium revenue (net of risk adjustment transfers), investment income, and other revenue. We believe total revenue is an important metric to assess the growth of our business, as well as the earnings potential of our investment portfolio. (2) Medical loss ratio (MLR) is a metric used to calculate medical expenses as a percentage of net premiums before ceded quota share reinsuranc… We believe MLR is an important metric to demonstrate the ratio of our costs to pay for the healthcare of our members to the net premiums before ceded quota share reinsuranc… (3) Selling, general, and administra… (SG&A) expense ratio is calculated as selling, general and administra… expenses as a percentage of total revenue (net of risk adjustment transfers). We believe the SG&A expense ratio is useful to evaluate our ability to manage our overall selling, general, and administra… cost base. (4) Earnings from operations is the Company's total revenue less total operating expenses. We believe earnings from operations is an important primary metric for assessing operating performanc…

• Total revenue was approximately $5.1 billion for the third quarter of 2026 compared to $3.0 billion for the third quarter of 2025. The increase was driven by rate increases and higher membership. Revenue for the third quarter of 2026 included a $250 million benefit from updated risk adjustment estimates, driven by favorable development in the Company’s risk scores relative to the market and modestly favorable market morbidity relative to expectations.

• The medical loss ratio was 84.0% for the third quarter of 2026 compared to 88.5% for the third quarter of 2025. The decrease was primarily driven by our disciplined pricing strategy. The Company had $42 million of favorable prior period development in the third quarter of 2026 compared to $84 million of favorable prior period development in the third quarter of 2025.

• The SG&A expense ratio was 14.0% for the third quarter of 2026 compared to 17.5% for the third quarter of 2025. The decrease was primarily due to lower risk adjustment as a percentage of premium, greater fixed cost leverage, and disciplined expense management.

• Earnings from operations were $178.0 million for the third quarter of 2026 compared to a loss from operations of $129.3 million for the third quarter of 2025. The significant increase reflects strong operating performance driven primarily by improved underwriting performance.

• Net income attributable to Oscar Health, Inc. was $167.3 million, or $0.49 of diluted earnings per share, for the third quarter of 2026 compared to net loss attributable to Oscar Health, Inc. of $137.5 million, or $(0.53) of diluted loss per share, for the third quarter of 2025.

• Adjusted EBITDA was $206.9 million for the third quarter of 2026 compared to an adjusted EBITDA loss of $101.5 million for the third quarter of 2025. 2

Oscar Health will host a conference call to discuss its financial results today, November 5, 2026, at 8:00 a.m. (ET). A live audio webcast will be available online via the Investor Relations page of Oscar Health’s website at ir.oscarhealth.com. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

This release presents adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release. For more information regarding adjusted EBITDA, please see “Key Operating and Non-GAAP Financial Metrics” below.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our financial outlook and estimates, including Total revenue, Medical loss ratio, SG&A expense ratio, Earnings (loss) from operations, and other financial performance metrics, and the related underlying assumptions, our business and financial prospects, including management’s plans and objectives for future operations, expectations and business strategy, such as our margins, market share and profitability, and industry and market dynamics and expected trends. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential,” or “continues” or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control.

Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our ability to execute our strategy and manage our growth effectively (including our ability to successfully integrate strategic acquisitions); our ability to retain and expand our member base; our ability to accurately estimate our incurred medical expenses or overall market morbidity, or effectively manage our medical costs or related administrative costs; unanticipated results of, or changes to, risk adjustment programs or our estimates thereof; evolving federal or state laws or regulations (including any changes in the interpretation or enforcement of existing laws and regulations), including changes with respect to the Patient Protection and Affordable Care Act (“ACA”) and any regulations enacted thereunder, the expiration of the enhanced Advanced Premium Tax Credits, the implementation of new program integrity rules, such as ID proofing rules, and rules pursuant to the Notice of Benefit and Payment Parameters for policy year 2027, the potential funding of a cost-sharing reduction program, or other government actions, such as the imposition of tariffs; our ability to achieve or maintain profitability in the future; our ability to arrange for the delivery of quality care and maintain good relations with brokers and the physicians, hospitals, and other providers within and outside our provider networks; our ability to comply with ongoing, complex and evolving regulatory requirements, including capital reserve and surplus requirements and applicable performance standards; changes or developments in the regulation of health insurance markets in the United States; our, or any of our vendors’, ability to comply with laws, regulations, and standards related to the handling of information about individuals or applicable consumer protection laws, including as a result of our participation in government-sponsored programs; the ability of our health insurance and Health Maintenance Organization subsidiaries to make payments of dividends or distributions to us, including to fund our business strategy; our ability to utilize quota share reinsurance to meet our capital and surplus requirements and protect against downside risk on medical claims; adverse market conditions resulting in our investment portfolio suffering losses or reducing our ability to meet our financing needs; unfavorable or otherwise costly outcomes of lawsuits, audits, investigations, and other third party claims that may arise from the extensive laws and regulations to which we are subject, such as fraud, waste and abuse laws; incurrence of data security breaches of our or our partners’ information and technology systems; heightened competition in the markets in which we participate; our ability to attract and retain qualified personnel; uncertainties associated with our utilization of certain artificial intelligence and machine learning models; our ability to detect and prevent material weaknesses or significant control deficiencies in our internal controls over financial reporting or other failure to maintain an effective system of internal controls; adverse publicity or other adverse consequences related to our dual class structure or “controlled company” status; and the other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”), and our other filings with the SEC. 3

You are cautioned not to place undue reliance on any forward-looking statements made in this press release. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.

Oscar Health, Inc. (NYSE: OSCR) is a leading consumer healthcare company that gives people power over their healthcare. Oscar Health serves millions of consumers, employers, brokers, and partners through Oscar Insurance, Lucie Health Marketplace, and Trove Group. Together these businesses deliver exceptional lifestyle products and technology platforms that make healthcare easy to choose, use, and experience. Learn more at OscarHealth.com.

(in thousands, except per September 30, December 31, share amounts) 2026 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current Assets: Cash and cash $ 4,466,858 $ 2,774,151 equivalents Short-term 3,021,732 1,216,461 investments Accounts receivable (net of allowance for credit 303,302 362,682 losses of $19,131 and $7,226) Reinsurance 270,643 99,750 recoverable Receivables 193,793 136,029 from CMS Other current 59,831 24,331 assets Total current 8,316,159 4,613,404 assets Long-term 1,441,909 1,470,987 investments Property, equipment, and 109,312 88,350 capitalized software, net Restricted 27,484 32,951 deposits Other assets 114,116 119,719 Total assets $ 10,008,980 $ 6,325,411 Liabilities and Stockholders' Equity Current Liabilities: Payables to CMS $ 4,626,054 $ 2,730,095 Benefits 1,924,075 1,455,385 payable Accounts payable and 589,220 507,325 other liabilities Unearned 160,392 166,203 premiums Reinsurance 1,711 3,579 payable Total current 7,301,452 4,862,587 liabilities Long-term debt 432,410 430,095 Other 49,324 51,994 liabilities Total 7,783,186 5,344,676 liabilities Commitments and contingencies Stockholders' Equity Class A common stock ($0.00001 par value; 825,000 thousand shares authorized, 275,454 thousand and 261,851 3 3 thousand shares outstanding as of September 30, 2026 and December 31, 2025, respectively) Class B common stock ($0.00001 par value; 82,500 thousand shares authorized, 35,176 thousand and 35,838 — — thousand shares outstanding as of September 30, 2026 and December 31, 2025, respectively) Treasury stock (315 thousand shares as of September -2,923 -2,923 30, 2026 and December 31, 2025) Additional 4,353,570 4,256,972 paid-in capital Accumulated -2,086,349 -3,294,434 deficit Accumulated other comprehensive -41,664 18,030 income (loss) Total Oscar Health, Inc. 2,222,637 977,648 stockholders' equity Noncontrolling 3,157 3,087 interests Total stockholders' 2,225,794 980,735 equity Total liabilities and $ 10,008,980 $ 6,325,411 stockholders' equity

(in thousands) Cash Flows from Nine Months Ended Operating September 30, Activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income (loss) $ 1,208,155 $ -90,469 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Change in provision 11,905 -24,020 for credit losses Stock-based 58,914 69,569 compensation expense Depreciation and 19,592 21,012 amortization expense Amortization of debt 3,339 774 issuance costs Net accretion of -22,975 -23,066 investments Deferred taxes -4,313 -175 Net realized gain on sale of financial -1,907 -1,302 instruments Changes in assets and liabilities: (Increase) / decrease in: Reinsurance -170,893 132,146 recoverable Accounts receivable 47,474 -54,402 Receivables from CMS -57,764 -78,240 Other assets -21,608 -29,759 Increase / (decrease) in: Payables to CMS 1,895,959 266,501 Benefits payable 468,691 207,665 Accounts payable and 83,847 58,061 other liabilities Unearned premiums -5,811 2,727 Reinsurance payable -1,868 -34,071 Net cash provided by operating 3,510,737 422,951 activities Cash Flows from Investing Activities: Sale of investments 1,149,495 134,231 Maturity and paydowns of 1,614,749 478,173 investments Change in restricted 211 3,225 deposits Purchase of -4,578,517 -780,673 investments Purchase of property, equipment, -31,864 -27,310 and capitalized software Net cash used in -1,845,926 -192,354 investing activities Cash Flows from Financing Activities: Proceeds from — 410,000 long-term debt Proceeds from exercise of stock options 41,828 42,192 and stock purchase agreement Tax payments related to net settlement -11,920 -4,035 of share-based awards Purchase of capped calls related to — -34,440 convertible notes Payments of debt -5,990 -22,677 issuance costs Earn-out liability -3,370 — payout Net cash provided by financing 20,548 391,040 activities Increase in cash, cash equivalents and 1,685,359 621,637 restricted cash equivalents Cash, cash equivalents, restricted cash 2,804,123 1,551,118 and cash equivalents—beginni… of period Cash, cash equivalents,restric… cash 4,489,482 2,172,755 and cash equivalents—end of period Cash and cash 4,466,858 2,148,865 equivalents Restricted cash and cash equivalents 22,624 23,890 included in restricted deposits Total cash, cash equivalents and $ 4,489,482 $ 2,172,755 restricted cash and cash equivalents Supplemental Disclosures: Interest payments $ 10,612 $ 11,515 Income tax payments $ 1,438 $ 17,497

We regularly review the following key operating and Non-GAAP financial metrics, to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions. We believe these operational and financial measures are useful in evaluating our performance, in addition to our financial results prepared in accordance with GAAP.

Total revenue includes premium revenue (net of risk adjustment transfers), investment income, and other revenues. We believe total revenue is an important metric to assess the growth of our business, as well as the earnings potential of our investment portfolio.

MLR is a metric used to calculate medical expenses as a percentage of net premiums before ceded quota share reinsurance. The impact of the federal risk adjustment program is included in the denominator of our MLR. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for healthcare of our members to the net premium before ceded quota share reinsurance.

The SG&A expense ratio reflects the Company’s selling, general, and administrative expenses, as a percentage of total revenue (net of risk adjustment transfers). We believe the SG&A expense ratio is useful to evaluate our ability to manage our overall selling, general, and administrative cost base.

Earnings (loss) from operations is the Company's total revenue less total operating expenses. We believe earnings (loss) from operations is an important primary metric for assessing operating performance.

Net income (loss) attributable to Oscar Health, Inc. is net earnings (loss) allocated to the Company after net income (loss) attributable to noncontrolling interests. It is a key indicator of the Company’s profitability and operational efficiency, allowing management to evaluate performance and make informed decisions on strategic planning, cost management, and resource allocation. 8

Adjusted EBITDA is defined as Net income (loss) for the Company and its consolidated subsidiaries before interest expense, income tax expense (benefit), and depreciation and amortization, as further adjusted for stock-based compensation and other items that are considered unusual or not representative of underlying trends of our business, where applicable for the period presented. We present Adjusted EBITDA because we believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations. We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner.

By providing this non-GAAP financial measure, together with a reconciliation to the most comparable U.S. GAAP measure, Net income (loss), we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for, net income (loss) or other financial statement data presented in our Condensed Consolidated Financial Statements as indicators of financial performance.

The Company records premium revenue net of premiums for reinsurance contracts accounted for under reinsurance accounting. The following table reconciles total reinsurance premiums ceded and reinsurance premiums assumed, which are included as components of total premium revenue in the Condensed Consolidated Statements of Operations:

The Company records medical expenses net of reinsurance recoveries for reinsurance contracts accounted for under reinsurance accounting. The following table reconciles total medical expenses to the amount presented in the Condensed Consolidated Statements of Operations:

The risk adjustment programs in the markets the Company serves are administered federally by CMS and are designed to mitigate the potential impact of adverse selection and provide stability for health insurers. Under these programs, each plan is assigned a risk score based upon demographic information and current year claims information related to its members. Plans with lower than average risk scores generally pay into the pool, while plans with higher than average risk scores generally receive distributions. The following table provides a rollforward of the Company’s beginning and ending risk adjustment receivable and payable balances for the nine months ended September 30, 2026 and 2025:

Full text with the tables
                      
  Oscar Health, Inc.  
  ir.oscarhealth.com  
  News Release        
                      
Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full
Year 2026 Outlook
                                                                                
  New York, NY, November 5, 2026 –                                              
                                                                                
Oscar Health, Inc. (“Oscar Health” or the “Company”) (NYSE: OSCR) announced
today its financial results for the third quarter ended September 30, 2026, and
updates to its full year 2026 outlook.

“Oscar Health is on track to deliver the strongest year of financial performance
in our history, and we are raising our earnings from operations outlook for a
third time,” said Mark Bertolini, CEO of Oscar Health. “The ACA is the
foundation of a rapidly-developing individual market in America, and Oscar
Health is built to lead it. Our disciplined pricing, consumer-led products, and
technology-powered approach are driving stronger economics and position us to
grow market share and expand margin in 2027.”
                                                                                
  Third Quarter 2026 Financial Highlights                                       
                                                                                
                                                                                
                    Three Months                     Nine Months                
                           Ended                           Ended                
                   September 30,                   September 30,                
  (in                                                                           
  thousands,                2026          2025              2026          2025  
  except                                                                        
  percentages)                                                                  
  Total revenue       $5,139,298    $2,985,984       $14,666,712    $8,896,192  
  Medical loss             84.0%         88.5%             78.1%         84.8%  
  ratio (“MLR”)                                                                 
  Selling,                                                                      
  general, and                                                                  
  administrati…            14.0%         17.5%             14.4%         17.3%  
  (“SG&A”)                                                                      
  expense ratio                                                                 
  Earnings                                                                      
  (loss) from           $178,018    $(129,250)        $1,270,738     $(62,610)  
  operations                                                                    
  Net income                                                                    
  (loss)                                                                        
  attributable          $167,281    $(137,450)        $1,208,085     $(90,540)  
  to Oscar                                                                      
  Health, Inc.                                                                  
  Adjusted              $206,852    $(101,453)        $1,349,273       $27,971  
  EBITDA(1)                                                                     
  (1) Adjusted                                                                  
  EBITDA is a                                                                   
  non-GAAP                                                                      
  measure. See                                                                  
  “Key                                                                          
  Operating and                                                                 
  Non-GAAP                                                                      
  Financial                                                                     
  Metrics -                                                                     
  Adjusted                                                                      
  EBITDA” in                                                                    
  this release                                                                  
  for a                                                                         
  reconciliati…                                                                 
  to net                                                                        
  income, the                                                                   
  most directly                                                                 
  comparable                                                                    
  GAAP measure,                                                                 
  and for                                                                       
  information                                                                   
  regarding                                                                     
  Oscar                                                                         
  Health’s use                                                                  
  of Adjusted                                                                   
  EBITDA.                                                                       
                                                                                
                                                                                
                                              As of September 30,               
  Effectuated Membership by Offering                         2026         2025  
  Individual and Small Group(1)                         2,691,885    2,111,736  
  Cigna+Oscar(2)                                                —        5,168  
  Total Members(3)                                      2,691,885    2,116,904  
  (1) Membership includes members enrolled                                      
  through a Custom Health Option and                                            
  Individual Care Expense Arrangement                                           
  (“CHOICE”). 2025 membership includes                                          
  small group members. The Company no                                           
  longer offers small group plans                                               
  effective December 15, 2024.                                                  
  (2) Represents total membership for our                                       
  former co-branded partnership with                                            
  Cigna. We did not renew the Cigna+Oscar                                       
  Small Group arrangement after its                                             
  initial term ended on December 31, 2024.                                      
  (3) Represents effectuated members.                                           
  Effectuated members are those who are                                         
  actively enrolled in one of our plans                                         
  and whose required premium payments have                                      
  either been made or are within the                                            
  payment grace period. A member covered                                        
  under more than one of our health plans                                       
  counts as a single member for the                                             
  purposes of this metric.                                                      
                                                                                
                                                                                
  2026                                                                          
  Financial                                                                     
  Guidance                                                                      
  Summary                                                                       
                 Prior Full                      Updated Full                   
                 Year 2026                       Year 2026                      
                 Outlook                         Outlook                        
  (in                                                                           
  thousands,     Low             High            Low              High          
  except                                                                        
  percentage…                                                                   
  Total          $18.7           $19.0           $19.0 billion    $19.3         
  revenue(1)     billion         billion                          billion       
  Medical                                                                       
  loss           81.0%           82.0%           80.5%            81.5%         
  ratio(2)                                                                      
  SG&A                                                                          
  expense        15.6%           16.1%           15.1%            15.6%         
  ratio(3)                                                                      
  Earnings                                                                      
  from           $600 million    $800 million    $850 million     $950 million  
  operations…                                                                   
  (1) Total                                                                     
  revenue                                                                       
  includes                                                                      
  premium                                                                       
  revenue                                                                       
  (net of                                                                       
  risk                                                                          
  adjustment                                                                    
  transfers),                                                                   
  investment                                                                    
  income, and                                                                   
  other                                                                         
  revenue. We                                                                   
  believe                                                                       
  total                                                                         
  revenue is                                                                    
  an                                                                            
  important                                                                     
  metric to                                                                     
  assess the                                                                    
  growth of                                                                     
  our                                                                           
  business,                                                                     
  as well as                                                                    
  the                                                                           
  earnings                                                                      
  potential                                                                     
  of our                                                                        
  investment                                                                    
  portfolio.                                                                    
  (2) Medical                                                                   
  loss ratio                                                                    
  (MLR) is a                                                                    
  metric                                                                        
  used to                                                                       
  calculate                                                                     
  medical                                                                       
  expenses as                                                                   
  a                                                                             
  percentage                                                                    
  of net                                                                        
  premiums                                                                      
  before                                                                        
  ceded                                                                         
  quota share                                                                   
  reinsuranc…                                                                   
  We believe                                                                    
  MLR                                                                           
  is an                                                                         
  important                                                                     
  metric to                                                                     
  demonstrate                                                                   
  the ratio                                                                     
  of our                                                                        
  costs to                                                                      
  pay for the                                                                   
  healthcare                                                                    
  of our                                                                        
  members to                                                                    
  the net                                                                       
  premiums                                                                      
  before                                                                        
  ceded quota                                                                   
  share                                                                         
  reinsuranc…                                                                   
  (3)                                                                           
  Selling,                                                                      
  general,                                                                      
  and                                                                           
  administra…                                                                   
  (SG&A)                                                                        
  expense                                                                       
  ratio is                                                                      
  calculated                                                                    
  as                                                                            
  selling,                                                                      
  general and                                                                   
  administra…                                                                   
  expenses as                                                                   
  a                                                                             
  percentage                                                                    
  of total                                                                      
  revenue                                                                       
  (net of                                                                       
  risk                                                                          
  adjustment                                                                    
  transfers).                                                                   
  We believe                                                                    
  the SG&A                                                                      
  expense                                                                       
  ratio is                                                                      
  useful to                                                                     
  evaluate                                                                      
  our ability                                                                   
  to manage                                                                     
  our overall                                                                   
  selling,                                                                      
  general,                                                                      
  and                                                                           
  administra…                                                                   
  cost base.                                                                    
  (4)                                                                           
  Earnings                                                                      
  from                                                                          
  operations                                                                    
  is the                                                                        
  Company's                                                                     
  total                                                                         
  revenue                                                                       
  less total                                                                    
  operating                                                                     
  expenses.                                                                     
  We believe                                                                    
  earnings                                                                      
  from                                                                          
  operations                                                                    
  is an                                                                         
  important                                                                     
  primary                                                                       
  metric for                                                                    
  assessing                                                                     
  operating                                                                     
  performanc…                                                                   
                                                                                
                                       1                                        
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
Third Quarter 2026 Key Metrics and Non-GAAP Financial Metrics

• Total revenue was approximately $5.1 billion for the third quarter of 2026
compared to $3.0 billion for the third quarter of 2025. The increase was driven
by rate increases and higher membership. Revenue for the third quarter of 2026
included a $250 million benefit from updated risk adjustment estimates, driven
by favorable development in the Company’s risk scores relative to the market and
modestly favorable market morbidity relative to expectations.

• The medical loss ratio was 84.0% for the third quarter of 2026 compared to
88.5% for the third quarter of 2025. The decrease was primarily driven by our
disciplined pricing strategy. The Company had $42 million of favorable prior
period development in the third quarter of 2026 compared to $84 million of
favorable prior period development in the third quarter of 2025.

• The SG&A expense ratio was 14.0% for the third quarter of 2026 compared to
17.5% for the third quarter of 2025. The decrease was primarily due to lower
risk adjustment as a percentage of premium, greater fixed cost leverage, and
disciplined expense management.

• Earnings from operations were $178.0 million for the third quarter of 2026
compared to a loss from operations of $129.3 million for the third quarter of
2025. The significant increase reflects strong operating performance driven
primarily by improved underwriting performance.

• Net income attributable to Oscar Health, Inc. was $167.3 million, or $0.49 of
diluted earnings per share, for the third quarter of 2026 compared to net loss
attributable to Oscar Health, Inc. of $137.5 million, or $(0.53) of diluted loss
per share, for the third quarter of 2025.

• Adjusted EBITDA was $206.9 million for the third quarter of 2026 compared to
an adjusted EBITDA loss of $101.5 million for the third quarter of 2025.
                                       2                                        
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
                                                                                
  Quarterly Conference Call Details                                             
                                                                                
Oscar Health will host a conference call to discuss its financial results today,
November 5, 2026, at 8:00 a.m. (ET). A live audio webcast will be available
online via the Investor Relations page of Oscar Health’s website at
ir.oscarhealth.com. A replay of the webcast will be available for on-demand
listening shortly after the completion of the call, at the same web link, and
will remain available for approximately 90 days.
                                                                                
  Non-GAAP Financial Information                                                
                                                                                
This release presents adjusted EBITDA, a non-GAAP financial metric, which is
provided as a complement to the results provided in accordance with accounting
principles generally accepted in the United States of America (“GAAP”). A
reconciliation of historical non-GAAP financial information to the most directly
comparable GAAP financial measure is provided in the accompanying tables found
at the end of this release. For more information regarding adjusted EBITDA,
please see “Key Operating and Non-GAAP Financial Metrics” below.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements other than
statements of historical fact contained herein are forward-looking statements.
These statements include, but are not limited to, statements about our financial
outlook and estimates, including Total revenue, Medical loss ratio, SG&A expense
ratio, Earnings (loss) from operations, and other financial performance metrics,
and the related underlying assumptions, our business and financial prospects,
including management’s plans and objectives for future operations, expectations
and business strategy, such as our margins, market share and profitability, and
industry and market dynamics and expected trends. In some cases, you can
identify forward-looking statements by terms such as “may,” “will,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,”
“contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential,”
or “continues” or the negative of these terms or other similar expressions.
Accordingly, we caution you that any such forward-looking statements are not
guarantees of future performance and are subject to risks, assumptions, and
uncertainties that are difficult to predict and generally beyond our control.

Although we believe that the expectations reflected in these forward-looking
statements are reasonable as of the date made, there are or will be important
factors that could cause our actual results to differ materially from those
indicated in these forward-looking statements, including, but not limited to,
the following: our ability to execute our strategy and manage our growth
effectively (including our ability to successfully integrate strategic
acquisitions); our ability to retain and expand our member base; our ability to
accurately estimate our incurred medical expenses or overall market morbidity,
or effectively manage our medical costs or related administrative costs;
unanticipated results of, or changes to, risk adjustment programs or our
estimates thereof; evolving federal or state laws or regulations (including any
changes in the interpretation or enforcement of existing laws and regulations),
including changes with respect to the Patient Protection and Affordable Care Act
(“ACA”) and any regulations enacted thereunder, the expiration of the enhanced
Advanced Premium Tax Credits, the implementation of new program integrity rules,
such as ID proofing rules, and rules pursuant to the Notice of Benefit and
Payment Parameters for policy year 2027, the potential funding of a cost-sharing
reduction program, or other government actions, such as the imposition of
tariffs; our ability to achieve or maintain profitability in the future; our
ability to arrange for the delivery of quality care and maintain good relations
with brokers and the physicians, hospitals, and other providers within and
outside our provider networks; our ability to comply with ongoing, complex and
evolving regulatory requirements, including capital reserve and surplus
requirements and applicable performance standards; changes or developments in
the regulation of health insurance markets in the United States; our, or any of
our vendors’, ability to comply with laws, regulations, and standards related to
the handling of information about individuals or applicable consumer protection
laws, including as a result of our participation in government-sponsored
programs; the ability of our health insurance and Health Maintenance
Organization subsidiaries to make payments of dividends or distributions to us,
including to fund our business strategy; our ability to utilize quota share
reinsurance to meet our capital and surplus requirements and protect against
downside risk on medical claims; adverse market conditions resulting in our
investment portfolio suffering losses or reducing our ability to meet our
financing needs; unfavorable or otherwise costly outcomes of lawsuits, audits,
investigations, and other third party claims that may arise from the extensive
laws and regulations to which we are subject, such as fraud, waste and abuse
laws; incurrence of data security breaches of our or our partners’ information
and technology systems; heightened competition in the markets in which we
participate; our ability to attract and retain qualified personnel;
uncertainties associated with our utilization of certain artificial intelligence
and machine learning models; our ability to detect and prevent material
weaknesses or significant control deficiencies in our internal controls over
financial reporting or other failure to maintain an effective system of internal
controls; adverse publicity or other adverse consequences related to our dual
class structure or “controlled company” status; and the other factors set forth
under the caption “Risk Factors” in our Annual Report on Form 10-K for the year
ended December 31, 2025, filed with the Securities and Exchange Commission
(“SEC”), and our other filings with the SEC.
                                       3                                        
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
You are cautioned not to place undue reliance on any forward-looking statements
made in this press release. Any forward-looking statement speaks only as of the
date as of which it is made, and, except as otherwise required by law, we do not
undertake any obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future developments or
otherwise. New factors emerge from time to time, and it is not possible for us
to predict which will arise.
                                                                                
  About Oscar Health                                                            
                                                                                
Oscar Health, Inc. (NYSE: OSCR) is a leading consumer healthcare company that
gives people power over their healthcare. Oscar Health serves millions of
consumers, employers, brokers, and partners through Oscar Insurance, Lucie
Health Marketplace, and Trove Group. Together these businesses deliver
exceptional lifestyle products and technology platforms that make healthcare
easy to choose, use, and experience. Learn more at OscarHealth.com.
                                                                                
  Investor Contact                                                              
                                                                                
:

Chris Potochar

VP of Investor Relations

[email protected]

Media Contact:

Dalya Browne

Senior Director, External Communications

[email protected]

Source: Oscar Health, Inc.
                                       4                                        
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
                                                                                
                               Oscar Health, Inc.                               
                                                                                
                                                                                
                                   Condensed                                    
                                                                                
                                                                                
                     Consolidated Statements of Operations                      
                                                                                
                                  (unaudited)                                   
                                                                                
  (in                                                                           
  thou…    Three                               Nine                             
  exce…    Months                              Months                           
  per      Ended                               Ended                            
  share    Septem…                             Septe…                           
  amou…    30,                                 30,                              
  Reve…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Prem…    $        5,041…    $     2,923,…    $       14,412…    $     8,723…  
  Inve…             91,016           53,215            236,424          153,3…  
  inco…                                                                         
  Other              6,295            8,801             18,108          19,628  
  reve…                                                                         
  Total             5,139…          2,985,…            14,666…          8,896…  
  reve…                                                                         
  Oper…                                                                         
  Expe…                                                                         
  Medi…             4,232…          2,586,…            11,257…          7,398…  
  Sell…                                                                         
  gene…             721,8…          521,592            2,119,…          1,538…  
  and                                                                           
  admi…                                                                         
  Depr…                                                                         
  and                6,543            7,312             19,621          21,012  
  amor…                                                                         
  Total                                                                         
  oper…             4,961…          3,115,…            13,395…          8,958…  
  expe…                                                                         
  Earn…                                                                         
  (los…             178,0…          -129,2…            1,270,…          -62,6…  
  from                                                                          
  oper…                                                                         
  Inte…              4,726            6,857             14,818          18,698  
  expe…                                                                         
  Other                                                                         
  expe…             -2,089            3,184             -1,245           3,308  
  (inc…                                                                         
  Earn…                                                                         
  (los…                                                                         
  befo…             175,3…          -139,2…            1,257,…          -84,6…  
  inco…                                                                         
  taxes                                                                         
  Inco…                                                                         
  tax                8,077           -1,807             49,010           5,853  
  expe…                                                                         
  (ben…                                                                         
  Net                                                                           
  inco…             167,3…          -137,4…            1,208,…          -90,4…  
  (los…                                                                         
  Less:                                                                         
  Net                                                                           
  inco…                                                                         
  (los…                 23              -34                 70              71  
  attr…                                                                         
  to                                                                            
  nonc…                                                                         
  inte…                                                                         
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  attr…    $        167,2…    $     -137,4…    $       1,208,…    $     -90,5…  
  to                                                                            
  Oscar                                                                         
  Heal…                                                                         
  Inc.                                                                          
  Earn…                                                                         
  (los…                                                                         
  per                                                                           
  Share                                                                         
  Basic    $          0.54    $       -0.53    $          3.98    $      -0.35  
  Dilu…    $          0.49    $       -0.53    $          3.59    $      -0.35  
  Weig…                                                                         
  Aver…                                                                         
  Comm…                                                                         
  Shar…                                                                         
  Outs…                                                                         
  Basic             309,3…          259,273            303,259          255,4…  
  Dilu…             346,4…          259,273            339,281          255,4…  
                                                                                
                                       5                                        
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
                                                                                
                               Oscar Health, Inc.                               
                                                                                
                                                                                
                                   Condensed                                    
                                                                                
                                                                                
                          Consolidated Balance Sheets                           
                                                                                
                                  (unaudited)                                   
                                                                                
                   (in thousands,                                               
                   except per             September 30,           December 31,  
                   share amounts)                  2026                   2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current Assets:                                                               
  Cash and cash                      $        4,466,858    $         2,774,151  
  equivalents                                                                   
  Short-term                                  3,021,732              1,216,461  
  investments                                                                   
  Accounts                                                                      
  receivable (net                                                               
  of allowance                                                                  
  for credit                                    303,302                362,682  
  losses of                                                                     
  $19,131 and                                                                   
  $7,226)                                                                       
  Reinsurance                                   270,643                 99,750  
  recoverable                                                                   
  Receivables                                   193,793                136,029  
  from CMS                                                                      
  Other current                                  59,831                 24,331  
  assets                                                                        
  Total current                               8,316,159              4,613,404  
  assets                                                                        
  Long-term                                   1,441,909              1,470,987  
  investments                                                                   
  Property,                                                                     
  equipment, and                                109,312                 88,350  
  capitalized                                                                   
  software, net                                                                 
  Restricted                                     27,484                 32,951  
  deposits                                                                      
  Other assets                                  114,116                119,719  
  Total assets                       $       10,008,980    $         6,325,411  
  Liabilities and                                                               
  Stockholders'                                                                 
  Equity                                                                        
  Current                                                                       
  Liabilities:                                                                  
  Payables to CMS                    $        4,626,054    $         2,730,095  
  Benefits                                    1,924,075              1,455,385  
  payable                                                                       
  Accounts                                                                      
  payable and                                   589,220                507,325  
  other                                                                         
  liabilities                                                                   
  Unearned                                      160,392                166,203  
  premiums                                                                      
  Reinsurance                                     1,711                  3,579  
  payable                                                                       
  Total current                               7,301,452              4,862,587  
  liabilities                                                                   
  Long-term debt                                432,410                430,095  
  Other                                          49,324                 51,994  
  liabilities                                                                   
  Total                                       7,783,186              5,344,676  
  liabilities                                                                   
  Commitments and                                                               
  contingencies                                                                 
  Stockholders'                                                                 
  Equity                                                                        
  Class A common                                                                
  stock ($0.00001                                                               
  par                                                                           
  value; 825,000                                                                
  thousand shares                                                               
  authorized,                                                                   
  275,454                                                                       
  thousand and                                                                  
  261,851                                             3                      3  
  thousand shares                                                               
  outstanding as                                                                
  of                                                                            
  September 30,                                                                 
  2026 and                                                                      
  December 31,                                                                  
  2025,                                                                         
  respectively)                                                                 
  Class B common                                                                
  stock ($0.00001                                                               
  par                                                                           
  value; 82,500                                                                 
  thousand shares                                                               
  authorized,                                                                   
  35,176 thousand                                                               
  and 35,838                                          —                      —  
  thousand shares                                                               
  outstanding as                                                                
  of                                                                            
  September 30,                                                                 
  2026 and                                                                      
  December 31,                                                                  
  2025,                                                                         
  respectively)                                                                 
  Treasury stock                                                                
  (315 thousand                                                                 
  shares as                                                                     
  of September                                   -2,923                 -2,923  
  30, 2026 and                                                                  
  December 31,                                                                  
  2025)                                                                         
  Additional                                  4,353,570              4,256,972  
  paid-in capital                                                               
  Accumulated                                -2,086,349             -3,294,434  
  deficit                                                                       
  Accumulated                                                                   
  other                                                                         
  comprehensive                                 -41,664                 18,030  
  income                                                                        
  (loss)                                                                        
  Total Oscar                                                                   
  Health, Inc.                                2,222,637                977,648  
  stockholders'                                                                 
  equity                                                                        
  Noncontrolling                                  3,157                  3,087  
  interests                                                                     
  Total                                                                         
  stockholders'                               2,225,794                980,735  
  equity                                                                        
  Total                                                                         
  liabilities and                    $       10,008,980    $         6,325,411  
  stockholders'                                                                 
  equity                                                                        
                                                                                
                                       6                                        
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
                                                                                
                               Oscar Health, Inc.                               
                                                                                
                                                                                
                Condensed Consolidated Statements of Cash Flows                 
                                                                                
                                  (unaudited)                                   
                                                                                
  (in thousands)                                                                
  Cash Flows from         Nine Months Ended                                     
  Operating               September 30,                                         
  Activities:             2026                                 2025             
 ────────────────────────────────────────────────────────────────────────────── 
  Net income (loss)       $                       1,208,155    $       -90,469  
  Adjustments to                                                                
  reconcile net income                                                          
  (loss) to net cash                                                            
  provided by                                                                   
  operating                                                                     
  activities:                                                                   
  Change in provision                                11,905            -24,020  
  for credit losses                                                             
  Stock-based                                        58,914             69,569  
  compensation expense                                                          
  Depreciation and                                   19,592             21,012  
  amortization expense                                                          
  Amortization of debt                                3,339                774  
  issuance costs                                                                
  Net accretion of                                  -22,975            -23,066  
  investments                                                                   
  Deferred taxes                                     -4,313               -175  
  Net realized gain on                                                          
  sale of financial                                  -1,907             -1,302  
  instruments                                                                   
  Changes in assets                                                             
  and liabilities:                                                              
  (Increase) /                                                                  
  decrease in:                                                                  
  Reinsurance                                      -170,893            132,146  
  recoverable                                                                   
  Accounts receivable                                47,474            -54,402  
  Receivables from CMS                              -57,764            -78,240  
  Other assets                                      -21,608            -29,759  
  Increase /                                                                    
  (decrease) in:                                                                
  Payables to CMS                                 1,895,959            266,501  
  Benefits payable                                  468,691            207,665  
  Accounts payable and                               83,847             58,061  
  other liabilities                                                             
  Unearned premiums                                  -5,811              2,727  
  Reinsurance payable                                -1,868            -34,071  
  Net cash provided by                                                          
  operating                                       3,510,737            422,951  
  activities                                                                    
  Cash Flows from                                                               
  Investing                                                                     
  Activities:                                                                   
  Sale of investments                             1,149,495            134,231  
  Maturity and                                                                  
  paydowns of                                     1,614,749            478,173  
  investments                                                                   
  Change in restricted                                  211              3,225  
  deposits                                                                      
  Purchase of                                    -4,578,517           -780,673  
  investments                                                                   
  Purchase of                                                                   
  property, equipment,                              -31,864            -27,310  
  and                                                                           
  capitalized software                                                          
  Net cash used in                               -1,845,926           -192,354  
  investing activities                                                          
  Cash Flows from                                                               
  Financing                                                                     
  Activities:                                                                   
  Proceeds from                                           —            410,000  
  long-term debt                                                                
  Proceeds from                                                                 
  exercise of stock                                                             
  options                                            41,828             42,192  
  and stock purchase                                                            
  agreement                                                                     
  Tax payments related                                                          
  to net settlement                                 -11,920             -4,035  
  of share-based                                                                
  awards                                                                        
  Purchase of capped                                                            
  calls related to                                        —            -34,440  
  convertible notes                                                             
  Payments of debt                                   -5,990            -22,677  
  issuance costs                                                                
  Earn-out liability                                 -3,370                  —  
  payout                                                                        
  Net cash provided by                                                          
  financing                                          20,548            391,040  
  activities                                                                    
  Increase in cash,                                                             
  cash equivalents and                            1,685,359            621,637  
  restricted cash                                                               
  equivalents                                                                   
  Cash, cash                                                                    
  equivalents,                                                                  
  restricted cash                                 2,804,123          1,551,118  
  and cash                                                                      
  equivalents—beginni…                                                          
  of period                                                                     
  Cash, cash                                                                    
  equivalents,restric…                                                          
  cash                                            4,489,482          2,172,755  
  and cash                                                                      
  equivalents—end of                                                            
  period                                                                        
  Cash and cash                                   4,466,858          2,148,865  
  equivalents                                                                   
  Restricted cash and                                                           
  cash equivalents                                   22,624             23,890  
  included in                                                                   
  restricted deposits                                                           
  Total cash, cash                                                              
  equivalents and         $                       4,489,482    $     2,172,755  
  restricted cash and                                                           
  cash equivalents                                                              
  Supplemental                                                                  
  Disclosures:                                                                  
  Interest payments       $                          10,612    $        11,515  
  Income tax payments     $                           1,438    $        17,497  
                                                                                
                                       7                                        
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
                                                                                
                  Key Operating and Non-GAAP Financial Metrics                  
                                                                                
We regularly review the following key operating and Non-GAAP financial metrics,
to evaluate our business, measure our performance, identify trends in our
business, prepare financial projections, and make strategic decisions. We
believe these operational and financial measures are useful in evaluating our
performance, in addition to our financial results prepared in accordance with
GAAP.
                                                                                
  Total Revenue                                                                 
                                                                                
Total revenue includes premium revenue (net of risk adjustment transfers),
investment income, and other revenues. We believe total revenue is an important
metric to assess the growth of our business, as well as the earnings potential
of our investment portfolio.
                                                                                
  MLR                                                                           
                                                                                
MLR is a metric used to calculate medical expenses as a percentage of net
premiums before ceded quota share reinsurance. The impact of the federal risk
adjustment program is included in the denominator of our MLR. We believe MLR is
an important metric to demonstrate the ratio of our costs to pay for healthcare
of our members to the net premium before ceded quota share reinsurance.
                                                                                
                Three                                Nine                       
  (in           Mont…                               Mont…                       
  tho…          Ended                               Ended                       
  exc…          Sept…                               Sept…                       
  per…    2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cla…                                                                          
  bef…                                                                          
  ced…    $     4,23…       $     2,58…       $     11,2…       $     7,39…     
  quo…                                                                          
  sha…                                                                          
  rei…                                                                          
  Net                                                                           
  pre…                                                                          
  bef…                                                                          
  ced…    $     5,04…       $     2,92…       $     14,4…       $     8,72…     
  quo…                                                                          
  sha…                                                                          
  rei…                                                                          
  Med…                                                                          
  Loss                                                                          
  Rat…           84.0  %           88.5  %           78.1  %           84.8  %  
  div…                                                                          
  by                                                                            
  B)                                                                            
                                                                                
                                                                                
  SG&A Expense Ratio                                                            
                                                                                
The SG&A expense ratio reflects the Company’s selling, general, and
administrative expenses, as a percentage of total revenue (net of risk
adjustment transfers). We believe the SG&A expense ratio is useful to evaluate
our ability to manage our overall selling, general, and administrative cost
base.
                                                                                
  Earnings (Loss) from Operations                                               
                                                                                
Earnings (loss) from operations is the Company's total revenue less total
operating expenses. We believe earnings (loss) from operations is an important
primary metric for assessing operating performance.

Net Income (Loss) Attributable to Oscar Health, Inc.

Net income (loss) attributable to Oscar Health, Inc. is net earnings (loss)
allocated to the Company after net income (loss) attributable to noncontrolling
interests. It is a key indicator of the Company’s profitability and operational
efficiency, allowing management to evaluate performance and make informed
decisions on strategic planning, cost management, and resource allocation.
                                       8                                        
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
                                                                                
  Adjusted EBITDA                                                               
                                                                                
Adjusted EBITDA is defined as Net income (loss) for the Company and its
consolidated subsidiaries before interest expense, income tax expense (benefit),
and depreciation and amortization, as further adjusted for stock-based
compensation and other items that are considered unusual or not representative
of underlying trends of our business, where applicable for the period presented.
We present Adjusted EBITDA because we believe it is frequently used by
securities analysts, investors, and other interested parties in the evaluation
of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management
believes that investors’ understanding of our performance is enhanced by
including this non-GAAP financial measure as a reasonable basis for comparing
our ongoing results of operations. We caution investors that amounts presented
in accordance with our definition of Adjusted EBITDA may not be comparable to
similar measures disclosed by our competitors, because not all companies and
analysts calculate Adjusted EBITDA in the same manner.

By providing this non-GAAP financial measure, together with a reconciliation to
the most comparable U.S. GAAP measure, Net income (loss), we believe we are
enhancing investors’ understanding of our business and our results of
operations, as well as assisting investors in evaluating how well we are
executing our strategic initiatives. Adjusted EBITDA has limitations as an
analytical tool, and should not be considered in isolation, or as an alternative
to, or a substitute for, net income (loss) or other financial statement data
presented in our Condensed Consolidated Financial Statements as indicators of
financial performance.
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
  (in              Septem…                            Septem…                   
  thousa…    2026      30,    2025              2026      30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  income     $     167,304    $     -137,484    $     1,208,…    $     -90,469  
  (loss)                                                                        
  Intere…            4,726             6,857           14,818           18,698  
  expense                                                                       
  Other                                                                         
  expens…           -2,089             3,184           -1,245            3,308  
  (incom…                                                                       
  Income                                                                        
  tax                8,077            -1,807           49,010            5,853  
  expense                                                                       
  (benef…                                                                       
  Earnin…                                                                       
  (loss)           178,018          -129,250          1,270,…          -62,610  
  from                                                                          
  operat…                                                                       
  Deprec…                                                                       
  and                6,543             7,312           19,621           21,012  
  amorti…                                                                       
  Stock-…           22,291            20,485           58,914           69,569  
  compen…                                                                       
  Adjust…    $     206,852    $     -101,453    $     1,349,…    $      27,971  
  EBITDA                                                                        
  (1)                                                                           
  Repres…                                                                       
  non-ca…                                                                       
  expens…                                                                       
  related                                                                       
  to                                                                            
  equity…                                                                       
  compen…                                                                       
  progra…                                                                       
  which                                                                         
  vary                                                                          
  from                                                                          
  period                                                                        
  to                                                                            
  period                                                                        
  depend…                                                                       
  on                                                                            
  various                                                                       
  factors                                                                       
  includ…                                                                       
  the                                                                           
  timing,                                                                       
  number,                                                                       
  and the                                                                       
  valuat…                                                                       
  of                                                                            
  awards.                                                                       
  Additi…                                                                       
  these                                                                         
  expens…                                                                       
  are                                                                           
  report…                                                                       
  net of                                                                        
  any                                                                           
  stock-…                                                                       
  compen…                                                                       
  that                                                                          
  has                                                                           
  been                                                                          
  capita…                                                                       
  for                                                                           
  softwa…                                                                       
  develo…                                                                       
  costs.                                                                        
                                                                                
                                       9                                        
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
                                                                                
                                    Appendix                                    
                                                                                
                                       10                                       
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
                                                                                
  Supplemental Financial Information                                            
                                                                                
                                                                                
  Premium                                                                       
                                                                                
The Company records premium revenue net of premiums for reinsurance contracts
accounted for under reinsurance accounting. The following table reconciles total
reinsurance premiums ceded and reinsurance premiums assumed, which are included
as components of total premium revenue in the Condensed Consolidated Statements
of Operations:
                                                                                
                    Three                               Nine                    
                   Months                             Months                    
                    Ended                              Ended                    
  (in             Septem…                            Septem…                    
  thous…    2026      30,    2025              2026      30,    2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Direct                                                                        
  policy    $     5,724,…    $     3,646,3…    $     17,421…    $     10,478,…  
  premi…                                                                        
  Risk                                                                          
  adjus…          -677,2…          -727,538          -2,991…          -1,793,…  
  trans…                                                                        
  Reins…                                                                        
  premi…           -5,133            -3,048          -15,740            -8,280  
  ceded                                                                         
  Assum…               37             8,246           -1,626            46,302  
  premi…                                                                        
  Premi…    $     5,041,…    $     2,923,9…    $     14,412…    $     8,723,2…  
  (1)                                                                           
  The                                                                           
  Compa…                                                                        
  did                                                                           
  not                                                                           
  renew                                                                         
  the                                                                           
  Cigna…                                                                        
  Small                                                                         
  Group                                                                         
  arran…                                                                        
  with                                                                          
  Cigna                                                                         
  Health                                                                        
  and                                                                           
  Life                                                                          
  Insur…                                                                        
  Compa…                                                                        
  after                                                                         
  its                                                                           
  initi…                                                                        
  term                                                                          
  ended                                                                         
  on                                                                            
  Decem…                                                                        
  31,                                                                           
  2024.                                                                         
  Follo…                                                                        
  termi…                                                                        
  the                                                                           
  Compa…                                                                        
  has                                                                           
  been                                                                          
  provi…                                                                        
  trans…                                                                        
  and                                                                           
  run-o…                                                                        
  servi…                                                                        
  and                                                                           
  will                                                                          
  conti…                                                                        
  to                                                                            
  provi…                                                                        
  such                                                                          
  servi…                                                                        
  throu…                                                                        
  Decem…                                                                        
  31,                                                                           
  2026.                                                                         
  The                                                                           
  Compa…                                                                        
  also                                                                          
  conti…                                                                        
  to                                                                            
  share                                                                         
  in                                                                            
  premi…                                                                        
  and                                                                           
  claims                                                                        
  for                                                                           
  plans                                                                         
  sold                                                                          
  or                                                                            
  issued                                                                        
  prior                                                                         
  to                                                                            
  Decem…                                                                        
  15,                                                                           
  2024.                                                                         
                                                                                
                                                                                
  Medical Expenses                                                              
                                                                                
The Company records medical expenses net of reinsurance recoveries for
reinsurance contracts accounted for under reinsurance accounting. The following
table reconciles total medical expenses to the amount presented in the Condensed
Consolidated Statements of Operations:
                                                                                
                    Three                               Nine                    
                   Months                             Months                    
                    Ended                              Ended                    
  (in             Septem…                            Septem…                    
  thous…    2026      30,    2025              2026      30,    2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Direct                                                                        
  claims    $     4,308,…    $     2,626,8…    $     11,474…    $     7,457,2…  
  incur…                                                                        
  Ceded                                                                         
  reins…          -76,116           -47,750          -217,1…          -100,965  
  claims                                                                        
  Assum…                                                                        
  reins…              897             7,250             -425            42,688  
  claims                                                                        
  Medic…    $     4,232,…    $     2,586,3…    $     11,257…    $     7,398,9…  
  expen…                                                                        
                                                                                
                                       11                                       
                                                                                
  Oscar Health, Inc.                                                            
                                                                                
                                                                                
  News Release                                                                  
                                                                                
                                                                                
  Risk Adjustment                                                               
                                                                                
The risk adjustment programs in the markets the Company serves are administered
federally by CMS and are designed to mitigate the potential impact of adverse
selection and provide stability for health insurers. Under these programs, each
plan is assigned a risk score based upon demographic information and current
year claims information related to its members. Plans with lower than average
risk scores generally pay into the pool, while plans with higher than average
risk scores generally receive distributions. The following table provides a
rollforward of the Company’s beginning and ending risk adjustment receivable and
payable balances for the nine months ended September 30, 2026 and 2025:
                                                                                
             Ni…                                 Ni…                            
             Mo…                                 Mo…                            
             En…                                 En…                            
             Se…                                 Se…                            
             30,                                 30,                            
             20…                                 20…                            
 ────────────────────────────────────────────────────────────────────────────── 
        Ri…         Ri…         Net         Ri…         Ri…          Net        
  (…    Ad…         Ad…         Ri…         Ad…         Ad…          Ri…        
  t…    Re…         Pa…         Ad…         Re…         Pa…          Ad…        
                                Pa…                                  Pa…        
  B…    $    56…    $    2,…    $    2,…    $    64…    $    1,5…    $    1,4…  
  b…                                                                            
  C…                                                                            
  in                                                                            
  a…                                                                            
  C…    $    45…    $    3,…    $    3,…    $    41…    $    1,7…    $    1,7…  
  y…                                                                            
  P…         56…         -2…         -5…         16…         92,…         76,…  
  y…                                                                            
  C…                                                                            
  in    $    10…    $    3,…    $    2,…    $    58…    $    1,8…    $    1,7…  
  a…                                                                            
  n…                                                                            
  P…                                                                            
  P…    $    27…    $    2,…    $    2,…    $    30…    $    1,6…    $    1,6…  
  y…                                                                            
  P…    $    27…    $    2,…    $    2,…    $    30…    $    1,6…    $    1,6…  
  E…                                                                            
  b…                                                                            
  C…    $    45…    $    3,…    $    3,…    $    41…    $    1,7…    $    1,7…  
  y…                                                                            
  P…         85…         29…         -5…         50…         11,…         -38…  
  y…                                                                            
  E…    $    13…    $    3,…    $    2,…    $    92…    $    1,7…    $    1,6…  
  b…                                                                            
  (…                                                                            
  T…                                                                            
  t…                                                                            
  i…                                                                            
  r…                                                                            
  a…                                                                            
  d…                                                                            
  v…                                                                            
  (…                                                                            
  r…                                                                            
  a…                                                                            
  p…                                                                            
  T…                                                                            
  b…                                                                            
  at                                                                            
  t…                                                                            
  b…                                                                            
  of                                                                            
  e…                                                                            
  y…                                                                            
  p…                                                                            
  p…                                                                            
  to                                                                            
  p…                                                                            
  p…                                                                            
  y…                                                                            
                                                                                
                                       12                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OSCR/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.